Funded Tech Companies

ImCheck Therapeutics

ImCheck Therapeutics, based in MARSEILLE Cedex 09, raised money from Pfizer Venture Investments, Alexandria Venture Investments and Invus.

Company Overview

Contact Information

Company Background Information

Overview

ImCheck Therapeutics is designing and developing novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (?9d2) T cells. Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic with a focus on ?9d2 T cells.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

6/13/2022

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Pierre d'Epenoux

        

Chief Financial Officer

Hans Christensen

        

Chief Medical Officer

Paul Frohna

        

Chief Scientific Officer

Loui Madakamutil

        

VP - Bus. Development

Claude Knopf

        

Company Investors

• Pfizer Venture Investments
• Alexandria Venture Investments
• Invus
• Wellington Partners
• Earlybird Venture Capital
• Agent Capital
• Bpifrance
• Andera Partners
• Eurazeo
• Kurma Partners
• Pureos Bioventures
• GIMV
• The Leukemia & Lymphoma Society

Browse more funded tech companies:

Imceda Software | iMedica

Share this article

About Our Venture Capital Database

This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary